Aixcrypto Holdings, INC. (AIXC) — SEC Filings

Overview

Aixcrypto Holdings, INC. (AIXC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: AIxCrypto Holdings, Inc. (AIXC) underwent a significant strategic realignment in 2025, pivoting from therapeutics to a dual-pillar strategy focused on Real-World Asset (RWA) tokenization and Embodied AI (EAI) infrastructure. The company raised $40.7 million in a PIPE financing in September 2025, inc

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 37 neutral, 5 mixed. The dominant filing sentiment for Aixcrypto Holdings, INC. is neutral.

Filing Type Overview

Aixcrypto Holdings, INC. (AIXC) has filed 2 10-K, 32 8-K, 3 DEF 14A, 3 S-1, 6 10-Q, 1 8-K/A, 3 S-1/A with the SEC between Jul 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• AIxCrypto Pivots to AI, Blockchain Infrastructure After $40.7M Raise — 10-K · Mar 30, 2026 Risk: high
  AIxCrypto Holdings, Inc. (AIXC) underwent a significant strategic realignment in 2025, pivoting from therapeutics to a dual-pillar strategy focused on Real-Worl
• 8-K Filing — 8-K · Dec 16, 2025
• AIxCrypto Sets Virtual 2024 Annual Meeting for Dec 30, Key Votes Ahead — DEF 14A · Dec 15, 2025 Risk: low
  AIxCrypto Holdings, Inc. (AIXC) is holding its 2024 Annual Meeting on December 30, 2025, virtually, to address key corporate governance matters. Stockholders wi
• AIxCrypto Pivots to Crypto Treasury, Secures $41M Private Placement — S-1 · Dec 4, 2025 Risk: high
  AIxCrypto Holdings, Inc. (AIXC) is undergoing a significant strategic pivot, transitioning from an early-clinical-stage therapeutics company to one focused on c
• AIxCrypto Holdings Files 8-K with Financials — 8-K · Nov 21, 2025 Risk: low
  AIxCrypto Holdings, Inc. (formerly Qualigen Therapeutics, Inc. and RITTER PHARMACEUTICALS INC) filed an 8-K on November 21, 2025, reporting events as of Novembe
• 8-K Filing — 8-K · Nov 20, 2025
• Qualigen Therapeutics Files 8-K with Corporate Updates — 8-K · Nov 17, 2025 Risk: low
  Qualigen Therapeutics, Inc. filed an 8-K on November 17, 2025, reporting events that occurred on November 12, 2025. The filing indicates amendments to its Artic
• Qualigen's Cash Soars 3200% on $41M Faraday-Backed Private Placement — 10-Q · Nov 14, 2025 Risk: medium
  Qualigen Therapeutics, Inc. (AIXC) reported a net loss of $6,369,407 for the nine months ended September 30, 2025, an increase from a net loss of $5,303,368 in
• Qualigen Seeks Shareholder Nod for Private Placement, Equity Plan — DEF 14A · Oct 20, 2025 Risk: medium
  Qualigen Therapeutics, Inc. (AIXC) is seeking stockholder approval for a private placement transaction from September 19, 2025, involving the issuance of 337,43
• Qualigen Therapeutics Changes Auditors to BDO USA — 8-K · Oct 7, 2025 Risk: medium
  Qualigen Therapeutics, Inc. announced on October 1, 2025, a change in its independent registered public accounting firm. The company dismissed Marcum LLP and ha
• Qualigen Therapeutics Files 8-K with Material Agreements — 8-K · Oct 3, 2025 Risk: medium
  On September 29, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• Qualigen Therapeutics Files 8-K on Officer/Director Changes — 8-K · Sep 29, 2025 Risk: low
  Qualigen Therapeutics, Inc. filed an 8-K on September 26, 2025, reporting on the departure of directors or certain officers, the election of directors, the appo
• Qualigen Therapeutics Files 8-K — 8-K · Sep 25, 2025 Risk: medium
  On September 19, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• Qualigen Therapeutics Files 8-K for Material Agreement — 8-K · Sep 16, 2025 Risk: medium
  On September 15, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement, likely a financing or debt arrangement, as indicated by the fil
• Qualigen Therapeutics Faces Delisting Notice — 8-K · Sep 8, 2025 Risk: high
  Qualigen Therapeutics, Inc. filed an 8-K on September 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's pri
• Qualigen Therapeutics Enters Material Definitive Agreement — 8-K · Aug 27, 2025 Risk: medium
  On August 21, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly know
• AIXC's Net Loss Widens 20% Amid Soaring G&A, Cash Dwindles — 10-Q · Aug 14, 2025 Risk: high
  Qualigen Therapeutics, Inc. (AIXC) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $4,331,588, up from $3,609,309 i
• Qualigen Therapeutics Files 8-K with Key Agreements and Equity Sales — 8-K · Jul 28, 2025 Risk: medium
  On July 28, 2025, Qualigen Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engage
• Qualigen Narrows Q1 Loss to $2.2M Amidst Ongoing Capital Raises — 10-Q · Jul 21, 2025 Risk: high
  Qualigen Therapeutics, Inc. (AIXC) reported a net loss of $2.2 million for the three months ended March 31, 2025, a significant improvement from the $4.1 millio
• Qualigen Therapeutics Files 8-K — 8-K · Jul 16, 2025 Risk: low
  On July 16, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Qualigen Therapeutics Navigates Pre-Revenue Stage with Capital Raises — 10-K · Jun 30, 2025 Risk: high
  Qualigen Therapeutics, Inc. reported no revenue for the fiscal year ended December 31, 2024, consistent with its pre-commercial stage as a pharmaceutical compan
• Qualigen Therapeutics Announces Board and Executive Changes — 8-K · Jun 24, 2025 Risk: medium
  Qualigen Therapeutics, Inc. announced on June 20, 2025, a series of significant corporate actions. These include the election of new directors, the appointment
• Qualigen Therapeutics Faces Delisting Concerns — 8-K · May 19, 2025 Risk: high
  Qualigen Therapeutics, Inc. filed an 8-K on May 19, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing indicates p
• Qualigen Therapeutics Faces Delisting Concerns — 8-K · May 1, 2025 Risk: high
  Qualigen Therapeutics, Inc. filed an 8-K on April 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerl
• Qualigen Therapeutics Files 8-K Report — 8-K · Jan 28, 2025 Risk: low
  On January 28, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation
• Qualigen Therapeutics Files 8-K: Security Holder Rights Modified — 8-K · Dec 26, 2024 Risk: medium
  Qualigen Therapeutics, Inc. announced on December 23, 2024, a material modification to the rights of its security holders. The company also filed financial stat
• Qualigen Therapeutics Files S-1 for Securities Offering — S-1 · Dec 9, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an S-1 registration statement on December 9, 2024, indicating plans to offer securities. The company, formerly known as Ritter
• Qualigen Therapeutics Files 8-K/A Amendment — 8-K/A · Nov 21, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an amendment (8-K/A) on November 21, 2024, to a previous report dated November 7, 2024. This amendment pertains to the departu
• Qualigen Therapeutics Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly Ritter Pharmaceuticals Inc., is incorporate
• Qualigen Therapeutics Announces Board and Executive Changes — 8-K · Nov 13, 2024 Risk: medium
  Qualigen Therapeutics, Inc. announced on November 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the de
• Qualigen Therapeutics Files 8-K on Security Holder Rights — 8-K · Nov 8, 2024 Risk: medium
  On November 5, 2024, Qualigen Therapeutics, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles o
• Qualigen Therapeutics Relocates Principal Executive Offices — 8-K · Nov 1, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a change in its principal executive offices to 5857 Owens Avenue, Suite 300, Carlsbad, C
• Qualigen Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Oct 29, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed an 8-K on October 29, 2024, reporting on matters submitted to a vote of security holders as of October 25, 2024. The filing in
• Qualigen Therapeutics Files S-1 Registration — S-1 · Oct 24, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an S-1 registration statement on October 24, 2024, to register securities under the Securities Act of 1933. The company, forme
• Qualigen Therapeutics Faces Nasdaq Delisting Warning — 8-K · Oct 22, 2024 Risk: high
  Qualigen Therapeutics, Inc. received a notification on October 18, 2024, indicating it is not in compliance with Nasdaq's minimum bid price requirement. The com
• Qualigen Therapeutics Appoints New Chief Medical Officer — 8-K · Oct 9, 2024 Risk: low
  On October 3, 2024, Qualigen Therapeutics, Inc. announced the appointment of Dr. Paul E. M. Mann as Chief Medical Officer. Dr. Mann brings extensive experience
• Qualigen Therapeutics Board Changes Announced — 8-K · Sep 26, 2024 Risk: medium
  Qualigen Therapeutics, Inc. announced on September 23, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new
• Qualigen Therapeutics Files 8-K — 8-K · Sep 20, 2024 Risk: low
  On September 20, 2024, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhi
• Qualigen Therapeutics Files Definitive Proxy Statement — DEF 14A · Sep 10, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed its definitive proxy statement on September 9, 2024, for its annual meeting. The filing details the company's operations and g
• Qualigen Therapeutics Enters Material Definitive Agreement — 8-K · Sep 9, 2024 Risk: medium
  Qualigen Therapeutics, Inc. announced on September 6, 2024, that it entered into a material definitive agreement. The company, formerly known as Ritter Pharmace
• Qualigen Therapeutics Files 8-K — 8-K · Sep 5, 2024 Risk: low
  Qualigen Therapeutics, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The filing details the company's corporate struc
• Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 22, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an S-1/A amendment on August 22, 2024, for its registration statement. The company, formerly known as Ritter Pharmaceuticals I
• Qualigen Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Specific financi
• Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 9, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an S-1/A amendment on August 9, 2024, for its registration statement. The company, formerly known as Ritter Pharmaceuticals In
• Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 7, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed an S-1/A amendment on August 7, 2024, related to its registration statement (No. 333-272623). The company, formerly known as R
• Qualigen Therapeutics Faces Nasdaq Delisting Warning — 8-K · Aug 5, 2024 Risk: high
  Qualigen Therapeutics, Inc. received a notification on August 2, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on t
• Qualigen Therapeutics Files 8-K: Material Definitive Agreement — 8-K · Jul 18, 2024 Risk: medium
  On July 12, 2024, Qualigen Therapeutics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, it
• Qualigen Therapeutics Secures $10M Loan from Innoviva — 8-K · Jul 15, 2024 Risk: medium
  On July 12, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement, a loan and security agreement with Innoviva, Inc. for a $10 million
• Qualigen Therapeutics Announces Change of Control and Executive Changes — 8-K · Jul 11, 2024 Risk: medium
  On July 5, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement related to a change in control of the company. The filing also announc
• Qualigen Therapeutics Files Q1 2024 10-Q — 10-Q · Jul 2, 2024 Risk: medium
  Qualigen Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detailing

Risk Profile

Risk Assessment: Of AIXC's 48 recent filings, 10 were flagged as high-risk, 25 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Aixcrypto Holdings, INC.'s most recent 10-K filing (Mar 30, 2026):

• Revenue: $0
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $40.7 million
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Kevin A. Richardson II
• Koti Meka
• Kevin Chen
• Jie Sheng
• Chad Chen
• Jiawei Wang
• Joseph Lucosky, Esq.
• Peter Campitiello, Esq.
• Dr. Paul E. M. Mann
• Dr. Paul J. Hastings
• Mr. Steven R. Smith
• Michael S. Poirier

Industry Context

AIxCrypto Holdings operates at the intersection of rapidly evolving sectors: blockchain technology, digital asset tokenization (specifically Real-World Assets - RWAs), and Embodied AI (EAI). The projected blockchain market growth to $1.9 trillion by 2034 from $41 billion in 2025, with over 50% CAGR, highlights the immense potential. However, this also signifies a highly competitive landscape with numerous startups and established tech players vying for market share in both RWA infrastructure and AI development.

Top Tags

Biotechnology (6) · material-agreement (5) · pharmaceuticals (5) · SEC Filing (4) · filing (4) · compliance (4) · sec-filing (4) · Private Placement (3) · 8-K (3) · corporate-update (3)

Key Numbers

• PIPE financing: $40.7 million — Raised in September 2025, funding digital asset treasury and Web3/AI initiatives.
• Strategic equity investment: $10 million — Anticipated investment in FFAI common stock for RWA tokenization.
• Registered wallets: 1 million — AIxC Hub surpassed this number by February 2026.
• Private placement: $4.2 million — Raised in July 2025 through Series A-3 Preferred Stock.
• IR Agency fee: $800,000 — Paid to IR Agency, LLC for investor relations services.
• Employees: 10 — As of December 31, 2025, indicating a lean operational structure.
• Market value of non-affiliate stock: $5,581,476 — As of June 30, 2025, based on $3.413 per share.
• Shares of Common Stock outstanding: 20,234,993 — As of March 23, 2026.
• Stock split: 1:50 — Effected on November 5, 2024, retroactively adjusted for all periods.
• Projected blockchain market: $1.9 trillion — By 2034, growing from $41 billion in 2025, representing over 50% CAGR.
• Common Stock Shares Outstanding: 7,049,999 — As of November 20, 2025 Record Date, each entitled to one vote
• Series B Convertible Preferred Stock Shares Outstanding: 39,943 — As of November 20, 2025 Record Date, each entitled to one vote
• Date of 2024 Annual Meeting: December 30, 2025 — Meeting will be held virtually at 9:00 a.m. Pacific Daylight Time
• Record Date for Voting: November 20, 2025 — Stockholders owning shares on this date are eligible to vote
• Number of Director Nominees: 5 — Stockholders will vote to elect five directors

Related Companies

FFAI · FFIE · QLGN · QGEN · QQQ · INVA

Frequently Asked Questions